Experimental Model of Cardiac Xenograft , Mouse Heart to Rat.
- Author:
Byung Il KIM
1
;
Sang Tae SON
;
Sung Ho SHIN
;
Won Sang JUNG
;
Hyuck KIM
;
Young Hak KIM
;
Jung Ho KANG
;
Heng Ok JEE
;
Churl Bum LEE
;
Jung Kook SUH
Author Information
1. Department of Thoracic & Cardiovascular Surgery, Korea University, College of Medicine.
- Publication Type:Original Article
- Keywords:
Transplantation;
heterologous;
Immunosuppression
- MeSH:
Allografts;
Animals;
Cyclosporine;
Heart*;
Heterografts*;
Humans;
Immunosuppression;
Mice*;
Models, Theoretical*;
Mortality;
Rats*;
Rodentia;
Splenectomy;
Tissue Donors;
Transplantation;
Transplantation, Heterologous
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
1999;32(1):1-4
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The transplantation of organs between phylogenetically disparate or harmonious species has invariably failed due to the occurrence of hyperacute rejection or accerelated acute rejection. But concordant cardiac xenograft offer us an opportunity to study xenotransplantation in the absence of hyperacute rejection. Current therapeutics for the prolongation of survival of rodent concordant xenotransplantation are not ideal with many regimens having a high mortality rate. Cyclosporine A & Mycophenolate Mofetil are new immunosuppresive agent which has been shown to be effective at prolonging survival of allograft, as purine synthesis inhibitor. MATERIAL AND METHOD: We used white mongrel rats as recipient and mice as donor, divided 4 groups(n=6), control group(Group 1) has no medication or pretreatment, Group 2 has splenectomy as pretreatment 7~10 days before transplantation, Group 3 has Cyclosporine A treatment group, Group 4 has combined treatment of Cyclosporine A & Mycophenolate Mofetil(RS 61443). We compared survival time. RESULT: We can't find significant difference of survival time between each groups. CONCLUSION: We concluded that rejection of cardiac xenograft was different from rejection of allograft, and new immunossuppresive Agent(Mycophenolate Mofetil, Cyclosporine A) was not effective for prolongation of survival time after cardiac xenograft.
